Selank Mechanism of Action
Part of the full Selank guide - a synthetic tuftsin-analogue heptapeptide reference compound, identity-verified with a COA on every vial.
In brief
Selank is studied in vitro and in preclinical neuro/immuno-signaling models as a synthetic tuftsin-analogue heptapeptide that modulates GABAergic neurotransmission, serotonergic signaling, and tuftsin-derived immune pathways. The following sections trace its reported receptor and signal-transduction behavior strictly as characterized in the laboratory literature, with no therapeutic or human-use claim.
The detail
A closer look
01
Tuftsin scaffold and the engineered PGP tail
Selank is built on the natural immunopeptide tuftsin (Thr-Lys-Pro-Arg) by appending a C-terminal Pro-Gly-Pro tripeptide, giving the full heptapeptide sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. This construction is the structural origin of its dual signaling identity: the tuftsin core (Thr-Lys-Pro-Arg) carries the immunopeptide heritage that links Selank to interferon and cytokine activity, while the appended PGP tail is the stability-determining module. Mechanistically, the PGP tail resists cleavage by prolyl endopeptidases, which markedly extends the molecule's stability over native tuftsin in research models. Because cleavage at proline-rich termini is the dominant degradation route for short peptides of this type, the protected tail is the proximate reason Selank persists long enough in model systems to engage downstream signaling rather than being rapidly hydrolyzed.
02
GABAergic signal modulation
In laboratory characterization, Selank is studied as a modulator of GABAergic neurotransmission and is reported as a positive influence on GABA-receptor-associated signaling. Rather than being described as a classical orthosteric agonist, the entry frames it at the level of receptor-associated signaling and downstream transcription: in gene-expression studies, Selank alters transcripts tied to GABAergic signaling. The Volkova et al. (2016) work cited for this entry specifically examined hippocampal expression of genes involved in GABAergic neurotransmission, situating Selank's reported mechanism at the intersection of receptor-associated signaling and measurable changes in the GABAergic transcriptional program in that brain region.
03
Serotonergic and immunomodulatory arms
Alongside its GABAergic profile, Selank is reported to exert serotonergic effects, placing it within anxiolytic-pathway signaling research at the in-vitro and preclinical level. Its immunomodulatory activity - acting on interferon and cytokine expression - is a direct reflection of its tuftsin heritage, since the tuftsin core (Thr-Lys-Pro-Arg) is the natural immunopeptide fragment from which Selank is derived. The same gene-expression studies that show altered GABAergic transcripts also report changes in immunity-related transcripts, so the GABAergic and immune signaling arms are characterized as concurrent, transcriptionally observable phenomena in the model systems studied, not as separate or sequential events.
04
Blood-brain-barrier permeability in models
Beyond stabilizing the molecule, the PGP tail is reported to improve blood-brain-barrier permeability in research models. This property is mechanistically relevant because it determines whether a peripherally introduced peptide can reach the central GABAergic and serotonergic compartments where its receptor-associated and transcriptional effects are measured. Improved CNS access in model systems is therefore part of the same structure-function story as the stability gain: the engineered C-terminal tripeptide is the single design element credited with both resisting prolyl-endopeptidase cleavage and enhancing penetration into neural tissue used in preclinical signaling assays.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. Selank is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.